NCT03086057

Brief Summary

"PrEPare for Work" is a two-stage randomized controlled pilot trial which utilizes a behavioral intervention to optimize the uptake and adherence of Pre-exposure Prophylaxis (PrEP) in Male Sex Workers (MSW).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
111

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started May 2017

Typical duration for not_applicable

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 8, 2017

Completed
14 days until next milestone

First Posted

Study publicly available on registry

March 22, 2017

Completed
1 month until next milestone

Study Start

First participant enrolled

May 1, 2017

Completed
2.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 15, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 15, 2019

Completed
1.2 years until next milestone

Results Posted

Study results publicly available

March 15, 2021

Completed
Last Updated

March 15, 2021

Status Verified

February 1, 2021

Enrollment Period

2.6 years

First QC Date

March 8, 2017

Results QC Date

February 3, 2021

Last Update Submit

February 22, 2021

Conditions

Keywords

PrEPPreventionMale Sex Workers (MSW)

Outcome Measures

Primary Outcomes (3)

  • Number of Participants With Verified Attendance at Initial Appointment at PrEP Clinic

    Number of participants with attendance at initial appointment at PrEP Clinic verified using medical records

    2-month post Stage 1 randomization

  • Number of Participants Who Initiated PrEP

    Initial prescription from provider filled and shown to study staff

    2-month post Stage 1 randomization

  • Number of Participants Reporting Optimal PrEP Adherence

    Self-reporting missing 0 PrEP pills in the past week

    6-months post Stage 2 randomization

Study Arms (4)

Strength Based Case Management

EXPERIMENTAL

Stage 1: Support, facilitate, and assist in linkage to PrEP clinic and to facilitate initiation of, and obtaining, PrEP medications.

Behavioral: PrEPare for Work: Strength Based Case Management (Stage 1)

PrEP adherence training and counseling

EXPERIMENTAL

Stage 2: Up to three adherence training and counseling intervention sessions (once per week for two to three weeks) with a clinical interventionist.

Behavioral: PrEPare for Work: Adherence Training and Counseling (Stage 2)

Standard of Care:Stage 1

NO INTERVENTION

Stage 1: Referral to The Miriam Hospital PrEP Clinic.

Standard of Care: Stage 2

NO INTERVENTION

Stage 2: Doctor visit every three months to assess for side effects and receive a HIV test.

Interventions

Support, facilitate, and assist in linkage to PrEP clinic and to facilitate initiation of, and obtaining, PrEP medications.

Strength Based Case Management

Up to three adherence training and counseling intervention sessions (once per week for two to three weeks) with a clinical interventionist.

PrEP adherence training and counseling

Eligibility Criteria

Age18 Years+
Sexmale(Gender-based eligibility)
Gender Eligibility DetailsBiological male at birth and current male gender identity
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • years of age or older
  • Biological male at birth and current male gender identity
  • Exchanged sex for money or drugs with another man in the past 3 months
  • Report behavioral risk for HIV infection, consistent with Centers for Disease Control and Prevention guidelines for prescribing PrEP: condomless anal intercourse with at least one HIV-infected or unknown serostatus partner in the past three months
  • HIV uninfected by antibody test\* Stage 2
  • Able to understand and speak English (for consent and counseling)
  • Mental competency to provide voluntary informed consent
  • Lives in the New England area
  • Willing to initiate PrEP

You may not qualify if:

  • Unable to provide informed consent, including as a result of severe mental illness requiring immediate treatment or mental illness limiting the ability to participate
  • HIV Positive at baseline
  • Infected with Hepatitis B or diagnosed with renal insufficiency (glomerular filtration rate \< 50) \*Stage 2
  • History of or current medical conditions that would preclude taking Truvada for PrEP \*Stage 2
  • Currently taking Truvada for PrEP

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

The Miriam Hospital

Providence, Rhode Island, 02906, United States

Location

Brown University School of Public Health

Providence, Rhode Island, 02912, United States

Location

MeSH Terms

Interventions

Counseling

Intervention Hierarchy (Ancestors)

Mental Health ServicesBehavioral Disciplines and ActivitiesCommunity Health ServicesHealth ServicesHealth Care Facilities Workforce and Services

Limitations and Caveats

Due to COVID, we are delayed in receiving the results of our biomarkers (specifically, hair analysis for PrEP adherence).

Results Point of Contact

Title
Dr. Katie Biello
Organization
Brown University

Study Officials

  • Matthew J Mimiaga, ScD, MPH

    Brown University, School of Public Health, Center for Health Equity Research

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Model Details: In Stage 1, individuals will be randomized (1:1) to receive the experimental PrEP navigation or standard of care. Among those who uptake PrEP in Stage 1, we will randomize those participants in Stage 2 (1:1) to receive the experimental adherence counseling or standard of care.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
ScD, MPH

Study Record Dates

First Submitted

March 8, 2017

First Posted

March 22, 2017

Study Start

May 1, 2017

Primary Completion

December 15, 2019

Study Completion

December 15, 2019

Last Updated

March 15, 2021

Results First Posted

March 15, 2021

Record last verified: 2021-02

Data Sharing

IPD Sharing
Will share

It is anticipated that this data will be presented annually on data collected after the second year when sufficient baseline data is collected. It is anticipated that most of the papers and data-based projects/presentations will happen in year 3, when all of the baseline data is collected, and the 3 month outcome has occurred for all participants. Sharing of the findings will involve a primary paper describing the study outcome and a paper that describes the intervention, as well as submitting to lead workshops on the intervention approach at relevant national meetings and conferences. Raw data for additional analysis will be available to outside individuals through contacting the MPIs. Information regarding the availability of data for analysis will be listed on the MPIs' web pages. Contact information for the MPIs will be listed in all manuscripts and publications as another means to access data.

Locations